Evolution of melanoma cross-resistance to CD8(+) T cells and MAPK inhibition in the course of BRAFi treatment

The profound but frequently transient clinical responses to BRAF(V600) inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way to further enhance therapeutic responses. However, to which extent B...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncoimmunology
Asıl Yazarlar: Pieper, Natalia, Zaremba, Anne, Leonardelli, Sonia, Harbers, Franziska Noelle, Schwamborn, Marion, Lübcke, Silke, Schrörs, Barbara, Baingo, Jolanthe, Schramm, Alexander, Haferkamp, Sebastian, Seifert, Ulrike, Sucker, Antje, Lennerz, Volker, Wölfel, Thomas, Schadendorf, Dirk, Schilling, Bastian, Paschen, Annette, Zhao, Fang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2018
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136878/
https://ncbi.nlm.nih.gov/pubmed/30221038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1450127
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller